This report on global peptide therapeutics market studies various type of application, delivery route, technology and geography. The advantages of using peptide-based molecules for treatment comprises low toxicity, excellent target specificity, high potency, good tolerance, and low incidence of side-effects. The disadvantages of peptide therapeutics are associated with their lack of oral bioavailability due to poor absorption across membrane, imposing parenteral injection as the normal mode of administration which leads to patient inconvenience and discomfort, and to non-compliance. In case competitive scenario of peptide therapeutics market, small biotech companies have seemed to be focusing on a single product or technology, while big pharmaceutical companies possess a diverse portfolio based on therapeutic areas and stresses on collaborations, mergers and acquisitions (M&A), and licensing.
For the purpose of this study, the various types of applications considered are cancer, cardiovascular diseases, metabolic diseases, central nervous system disorders, respiratory diseases, infectious diseases, gastrointestinal diseases, renal disorders, and others (pain management, dermatological disorders, and hematological disorders). Market size estimates and forecast for these segments for the period 2014 to 2024 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2024, considering 2015 as the base year.
The market segmentation on the basis types of delivery route comprises sub-segments such as oral route, parenteral route, pulmonary route, mucosal route, and other routes (intradermal & nasal). Market size estimates and forecast for these segments for the period 2014 to 2024 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2024, considering 2015 as the base year.
The market segmentation on the basis types of technology includes sub-segments such as solid phase peptide synthesis (SPPS), liquid phase peptide synthesis (LPPS), and hybrid phase peptide synthesis (HPPS). Market size estimates and forecast for these segments for the period 2014 to 2024 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2024, considering 2015 as the base year.
The geographic segmentation of the global peptide therapeutics market includes regions such as North America, Europe, Asia-Pacific, Latin America and Middle East & Africa markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecast for these segments for the period 2014 to 2024 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2024, considering 2015 as the base year.
The key players covered in peptide therapeutics market are Amgen Inc., Amylin Pharmaceuticals LLC (Bristol- Myers Squibb), AstraZeneca plc, Bachem Holding AG, Eli Lilly and Company, GlaxoSmithKline plc, Ipsen, Lonza, Inc., Merck & Co., Novartis AG, Novo- Nordisk A/S, Peptisyntha, PolyPeptide Group, Pfizer, Inc., F. Hoffman-La Roche AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, and Teva Pharmaceuticals.
Based on the type of technology, the peptide therapeutics market is segmented into:
In 2015, solid phase peptide synthesis accounted for the largest market share due to introduction of novel products equipped with SPPS especially focusing on oral route of drug delivery. Some of the examples such as initially Unigene and then Enteris Biopharma developed a technology named Peptelligence which is based on an enteric-coated tablet, whose core formulation contains, in addition to the peptide, an organic acid enzyme inhibitor and a permeation enhancer which is claimed to help penetrate the mucus layer. Merrion Pharmaceuticals is also developing the GIPET technology using an enteric coating to protect the peptide in the acidic gastric medium and ensure peptide release in the small intestine. Thus, several other technologies have been under clinical trials and are expected to enter market in the near future. During the forecast period 2016 – 2024, HPPS was observed as the fastest growing segment due to its increasing adoption in peptide drug manufacturing.
Peptide market is growing much faster than that of small molecules, and will make up an even larger proportion of the market in the future. Currently there are over 100 approved peptide-based therapeutics on the market, with the majority being smaller than 20 amino acids. Compared with the typical small-molecule drugs that currently make up the majority of the pharmaceutical market, peptides and proteins can be highly selective as they have multiple points of contact with their target. Based on the type of delivery route, the peptide therapeutics market is segmented into:
These peptide and protein therapeutics have disadvantages as well, such as low bioavailability and metabolic liability. Oral bioavailability of peptides is limited by degradation in the gastrointestinal (GI) tract as well as their inability to cross the epithelial barrier. These therapeutics tend to have high molecular weights, low lipophilicity and charged functional groups that hamper their absorption. Thus, routes which were of minor importance as parts of drug delivery in the past have assumed added importance in protein and delivery and these include nasal, ophthalmic, buccal, rectal, intrauterine, vaginal, transdermal and pulmonary routes. The oral, nasal and pulmonary route have been the primary non-invasive routes of protein delivery investigated to research in this field to despite the observation that bioavailability of the peptide and proteins have been proven to be very low in most of the non-invasive routes tested. The research & development experts from this field suggested that peptides and proteins are swiftly metabolized in the GI tract, and the hydrophilic nature of most natural peptides constrains movement across the epithelial barrier. Developments in the oral delivery of proteins and peptides have been made by the use of absorption enhancers, enzyme inhibitors and direct structural modification of the therapeutic.
Based on the type of applications, the peptide therapeutics market is segmented into:
In 2015, cancer segment accounted of the major market share due to rising prevalence of cancers coupled with high disease diagnosis rate, rising public awareness associated with the peptide therapeutics and developing overall healthcare infrastructure and supportive government policies. It was also observed that, naturally occurring peptides are most of the times not directly suitable for its application as convenient therapeutics due to factors such as intrinsic weaknesses, a short circulating plasma half-life, and poor chemical and physical stability. The key disease areas presently driving the therapeutic applications of peptide drugs are oncology and metabolic diseases. The factors aiding epidemic growth of metabolic diseases are both obesity and T2DM, in case of oncology by rising mortality and need for chemotherapy replacement along with cancer supportive care. The application of peptide therapeutics in the treatment of diabetes and obesity is possibly the reason behind largest share of North America in the global peptide drug market, with the Asia-Pacific reflecting the largest growth. However, a current trend observed recently was shifted focus of companies towards the infectious diseases and inflammation or pain management, where several peptides are undergoing clinical testing.
North America was observed as the largest market in peptide therapeutics industry due to factors such as high awareness associated with therapeutic treatment developments in public, high acceptance for novel products and technologies from patients and medical practitioners, and high healthcare costs. The European peptide therapeutics market has also projected noticeable growth due to factors such as increasing research and development activities associated with peptide therapeutics, and major merger and acquisitions were observed in Europe peptide therapeutics industry. In addition, the major factor that has fueled the research and development activity in Europe peptide therapeutics industry are rising obesity cases and high prevalence of cardiovascular disorders. In Asia-Pacific excluding Japan other countries are at a nascent stage as compared to the more mature markets of North America and Europe. However, countries such as China, Australia and New Zealand are anticipated to be the largest markets for peptide therapeutics and collectively accounted for 78.4% revenue share in year 2015 of the total Asia-Pacific market (except Japan).
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Peptide Therapeutics market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2022-2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Year | 2022 |
| Unit | USD Million |
| Segmentation | |
Technology
| |
Delivery Route
| |
Applications
| |
|
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report
